A recent important finding, based on epidemiological analysis, reveals the connection between DSF and reduced cancer mortality and identifies the p97 segregase adaptor NPL4 as the anticancer target of DSF.48 The DSF-based therapy provides promise for cancer patients due to the ready availability of a low-cost drug with an already well-established PK, safety, and tolerance. Here, NPLOC4 is linked to cancer.